Different Doses – Different Names

July 13, 2012 @ 6:03 am
posted by Dr Ginther

We have talked about Reclast and Prolia, two meds for osteoporosis.  We have not talked about Zometa and Xgeva, two meds for prevention and treatment of cancer spreading to bone (metastases).  We should.

Reclast and Zometa are the same drug (Zolendronate) given in different doses for different diseases.  Prolia and Xgeva  are the same drug (Denosumab) given in different doses for different diseases. 

Last week NEJM published a study that looked at actual total Vitamin D intake by individuals (65 and older) in the study.  No previous study had divided individuals by their total Vitamin D intake (their assigned supplement + what they were already taking) and also asked how often they actually took their meds.

Those taking total 800 IU Vit D or more daily showed a 30% decrease in hip fractures.  This is highly significant.  This is also the first time persons taking 800 IU daily were studied.  When all individuals assigned to (400 IU) Vit D were combined (including those rarely taking their assigned dose) the 10% decrease in hip fractures was not statistically significant.

Focus on Blue Zones

July 6, 2012 @ 6:03 am
posted by Dr Ginther

Waterloo & Cedar Falls, IA move on to Blue Zones Focus Groups next week.  This is the chance for local input as we move toward identifying which specific projects we will choose to initiate.

Topics are:  School and Community Policy;  Employer, Grocery, and Restaurants;  Volunteering, Engagement, and Purpose.  Pick your favorite.  Meetings are 4:30-6:30 pm at Wloo West and CF High respectively.  For specific date and location of each topic go to:  bluezonesprojectwaterloo@healthways.com or bluezonesprojectcedarfalls@healthways.com.

I will attend Employers, Grocery, Restaurants.   Nutrition is a key aspect of good bone health.  Making foods high in calcium easier to identify will be an obvious step forward for bone health. 

Prolia for Men Too – A Few Men

July 2, 2012 @ 7:11 am
posted by Dr Ginther

Prolia has been available for postmenopausal women for 2 years.  It is the only Antiresorptive appropriate for persons with both reflux disease (GERD) and decreased renal function (mild kidney failure).  But it was not FDA approved for men.  Now it is approved, but only for a few men.

Men with Prostate Cancer taking medications to eliminate Testosterone (hormonal ablation) and without metastases (cancer spread to bone and other tissues) are now approved for Prolia.  Prolia can delay the spread of cancer to bone, sometimes for years.  All other men must wait for studies demonstrating that Prolia works on osteoporosis the same in  men as in women.